Optym Raises Strategic Funding From Venture 53 To Make Transportation Operations Efficient
Venture 53, an industry-focused transportation and logistics fund, recently announced their investment in Optym, a trailblazer in optimization solutions for the transportation industry. Founded in 2000 by UF Professor Emeritus Ravi Ahuja, Optym serves railroads, airlines, and truck carriers to improve efficiency and optimization through AI.
First Patient Enrolled in Rise Therapeutics’ Rheumatoid Arthritis Clinical Trial
Rise Therapeutics, a UF startup and a clinical-stage biotechnology company developing novel oral immunotherapeutic medicines, announced it has enrolled its first patient in its R-2487 Phase 1 rheumatoid arthritis clinical trial.
Axogen Announces Plan for CEO Leadership Transition
UF startup and UF Innovate | Sid Martin Biotech alum Axogen, Inc., a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that President and Chief Executive Officer (CEO) Karen Zaderej plans to retire from the company by January 2025.
Hernando County Government Streamlines Permitting Process With AutoReview.AI
The Hernando County Board of County Commissioners recently approved the onboarding of AutoReview.AI to streamline the permit approval process and review development plans for compliance purposes.
AutoReview.AI, a UF startup and UF Accelerate resident client, specializes in elevating efficiency by reviewing land and permits in seconds using their artificial intelligence technology. This ensures accuracy when tracking compliance and allows planners to focus on the more specific and nuanced parts of community development.
Atsena Therapeutics Announces Positive 12-Month Safety and Efficacy Data From Ongoing Phase I/II Clinical Trial To Treat Leber Congenital Amaurosis
Atsena Therapeutics announced positive results in their 12-month safety and efficacy data from the ongoing Phase I/II trial of ATSN-101, the company’s investigational gene therapy for the treatment of GUCY2D-associated Leber congenital amaurosis (LCA1). At 12 months post-treatment, ATSN-101 has conferred clinically meaningful improvements in vision at the highest dose with no serious treatment-emergent adverse events.
Enterade Partners With 7-Time Olympic Medalist and Cancer Survivor Shannon Miller
UF Innovate startup company Enterade has teamed up with 7-time Olympic medalist, gymnast, and cancer survivor Shannon Miller to promote their non-prescription medical drink as a key part of the chemotherapy healing and recovery process.
Study Provides Preliminary Evidence in Favor of a New Type 1 Diabetes Treatment
Researchers have discovered preliminary evidence for a new type 1 diabetes treatment using the drug DFMO, supplied by UF startup Panbela Therapeutics.
UF Startup RedoxBlox Receives Funding From California Energy Commission as Part of Long-Duration Energy Storage Project
UF startup RedoxBlox recently received $8,936,778 in funding from the California Energy Commission aimed at improving resilience and reliability among low-income and disadvantaged communities.
Atsena Therapeutics Receives FDA Designation for Treatment of Severe Congenital Eye Disease Using Gene Therapy
Atsena Therapeutics has been granted Regenerative Medicine Advanced Therapy designation from the FDA to continue their research on a cure to Leber congenital amaurosis. Patients with this disease are missing a gene that regulates retinal function and visually-guided behavior, causing blindness at an early age.
New Pest Management Hub Will Address Florida’s Buggiest Problems
The University of Florida Institute of Food and Agricultural Sciences (UF/IFAS) will create a new network focused on finding novel ways to manage bugs and pests in homes and businesses, known as the Innovation Hub for Urban Pest Management.
